"Soluble Guanylyl Cyclase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A mammalian enzyme composed of a heterodimer of alpha and beta subunits. Each subunit consists of four domains; N-terminal HNOX domain, PAS-like domain, a coiled-coil domain, and a C-terminal catalytic domain. All four domains are homologous proteins with a similar conformation of functional domains. Soluble guanylate cyclase catalyzes the formation of cyclic GMP from GTP, and is a key enzyme of the nitric oxide signaling pathway involved in the regulation of a variety of biological and physiological processes in mammals.
| Descriptor ID |
D000071756
|
| MeSH Number(s) |
D08.811.520.650.600.750 D12.644.360.350.500 D12.776.476.350.500
|
| Concept/Terms |
Soluble Guanylyl Cyclase- Soluble Guanylyl Cyclase
- Cyclase, Soluble Guanylyl
- Guanylyl Cyclase, Soluble
- Soluble Guanylate Cyclase
- Cyclase, Soluble Guanylate
- Guanylate Cyclase, Soluble
- Nitric Oxide-Sensitive Guanylyl Cyclase
- Nitric Oxide Sensitive Guanylyl Cyclase
- Receptor, Nitric Oxide
- Nitric Oxide Receptor
- Oxide Receptor, Nitric
- Nitric Oxide Receptors
- Oxide Receptors, Nitric
|
Below are MeSH descriptors whose meaning is more general than "Soluble Guanylyl Cyclase".
Below are MeSH descriptors whose meaning is more specific than "Soluble Guanylyl Cyclase".
This graph shows the total number of publications written about "Soluble Guanylyl Cyclase" by people in this website by year, and whether "Soluble Guanylyl Cyclase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Soluble Guanylyl Cyclase" by people in Profiles.
-
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 10; 54(4).
-
Acute stimulation of the soluble guanylate cyclase does not impact on left ventricular capacitance in normal and hypertrophied porcine hearts in vivo. Am J Physiol Heart Circ Physiol. 2018 09 01; 315(3):H669-H680.
-
Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Ann Rheum Dis. 2018 03; 77(3):459.
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. JACC Heart Fail. 2018 02; 6(2):96-104.
-
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail. 2017 06; 19(6):782-791.
-
Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respir Med. 2017 07; 128:50-56.
-
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017 04 14; 38(15):1119-1127.